{"id":"biological-oral-polio-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) shedding"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":"rare","effect":"Vaccine-associated paralytic poliomyelitis (VAPP) in immunocompromised recipients"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains three serotypes of live attenuated poliovirus that replicate in the intestinal mucosa, triggering both mucosal (IgA) and systemic (IgG) immune responses. This oral route of administration induces intestinal immunity and prevents viral shedding, providing protection against wild-type poliovirus infection and contributing to herd immunity through vaccine virus transmission.","oneSentence":"Oral polio vaccine stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by delivering live attenuated (weakened) virus that replicates in the gastrointestinal tract.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:21.566Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention in infants and children"}]},"trialDetails":[{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06331156","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-03-22","conditions":"Gastroenteritis","enrollment":400},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT01375647","phase":"PHASE3","title":"Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2011-05","conditions":"Rotavirus Diarrhea, Vaccine Virus Shedding, Tropical Enteropathy","enrollment":700},{"nctId":"NCT06218368","phase":"NA","title":"A Tool Kit to Improve Vaccine Confidence in the Philippines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Toronto","startDate":"2024-01-31","conditions":"Measles, Polio, Vaccination Hesitancy","enrollment":5400},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT03460002","phase":"PHASE4","title":"Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2016-11","conditions":"Measles Vaccination, Oral Polio Vaccine, Non-specific/Heterologous Effects of Vaccines","enrollment":28612},{"nctId":"NCT02961595","phase":"PHASE1","title":"Live Enterovirus Vaccine and Type 1 Diabetes","status":"COMPLETED","sponsor":"Tampere University","startDate":"1999-10","conditions":"Enterovirus Infection, Type 1 Diabetes, Prediabetic State","enrollment":315},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT06266754","phase":"PHASE4","title":"The Non-Specific Immunological Effects of Providing Oral Polio Vaccine to Seniors in Guinea-Bissau","status":"UNKNOWN","sponsor":"Bandim Health Project","startDate":"2024-01-29","conditions":"Vaccine Reaction","enrollment":80},{"nctId":"NCT06114810","phase":"PHASE4","title":"Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-11","conditions":"Polio","enrollment":880},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT02580201","phase":"PHASE4","title":"A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-11","conditions":"Poliomyelitis","enrollment":154},{"nctId":"NCT05083039","phase":"","title":"Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19","status":"COMPLETED","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2020-05-14","conditions":"Coronavirus Infections, Vaccine, Polio","enrollment":1500},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT03581734","phase":"PHASE3","title":"Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-01","conditions":"Vaccine Reaction","enrollment":579},{"nctId":"NCT04445428","phase":"PHASE4","title":"OPV as Potential Protection Against COVID-19","status":"UNKNOWN","sponsor":"Bandim Health Project","startDate":"2020-07-15","conditions":"Poliovirus Vaccine, Oral, COVID, Mortality","enrollment":3400},{"nctId":"NCT00625482","phase":"NA","title":"Sex-Differential Health Interventions In Low-Birth-Weight Infants","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2008-02","conditions":"Mortality, Morbidity, Growth","enrollment":""},{"nctId":"NCT03202719","phase":"PHASE4","title":"Duration of IPV Priming and Antibody Decay","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-11-05","conditions":"Poliomyelitis","enrollment":1645},{"nctId":"NCT00263666","phase":"PHASE2","title":"A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-16","conditions":"Infections, Rotavirus","enrollment":100},{"nctId":"NCT04540185","phase":"PHASE3","title":"A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2020-11-01","conditions":"Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection","enrollment":3600},{"nctId":"NCT01021293","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-28","conditions":"Poliomyelitis, Poliomyelitis Vaccines","enrollment":1101},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00678301","phase":"PHASE3","title":"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-18","conditions":"Infections, Streptococcal","enrollment":365},{"nctId":"NCT02408926","phase":"PHASE4","title":"Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2015-04","conditions":"Pertussis","enrollment":370},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT02766816","phase":"PHASE3","title":"A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals","status":"COMPLETED","sponsor":"Bilthoven Biologicals","startDate":"2016-06-08","conditions":"Immune Response to Oral Polio Vaccine","enrollment":1120},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT01098474","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-07","conditions":"Tuberculosis","enrollment":301},{"nctId":"NCT01262872","phase":"PHASE2","title":"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-09","conditions":"Infections, Streptococcal","enrollment":1320},{"nctId":"NCT01175083","phase":"PHASE3","title":"Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-01","conditions":"Infections, Streptococcal","enrollment":300},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03821441","phase":"PHASE3","title":"Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-01-04","conditions":"Poliomyelitis","enrollment":1165},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT01616693","phase":"PHASE4","title":"Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2012-07","conditions":"Immunity to Oral Rotavirus Vaccine, Immunity to Oral Polio Vaccine, Shedding of Oral Rotavirus Vaccine","enrollment":620},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT02062385","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-30","conditions":"Rotavirus Gastroenteritis","enrollment":4040},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01926015","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-19","conditions":"Rotavirus Disease","enrollment":192},{"nctId":"NCT00829010","phase":"PHASE3","title":"Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-17","conditions":"Infections, Streptococcal","enrollment":489},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT01231503","phase":"PHASE2","title":"Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-13","conditions":"Malaria","enrollment":480},{"nctId":"NCT01171963","phase":"PHASE3","title":"Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-29","conditions":"Infections, Rotavirus","enrollment":3340},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT01571505","phase":"PHASE1","title":"Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2012-03-01","conditions":"Poliomyelitis, Tropical Enteropathy","enrollment":372},{"nctId":"NCT01056705","phase":"PHASE2","title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2009-07","conditions":"Poliomyelitis","enrollment":500},{"nctId":"NCT00514709","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1843},{"nctId":"NCT02785705","phase":"PHASE3","title":"Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine","status":"COMPLETED","sponsor":"Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":600},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT00130832","phase":"PHASE3","title":"Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Rotavirus Infections, Gastroenteritis","enrollment":735},{"nctId":"NCT00348387","phase":"PHASE3","title":"Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Poliomyelitis, Polio","enrollment":600},{"nctId":"NCT00343889","phase":"PHASE3","title":"Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-08","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":379},{"nctId":"NCT00534833","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":362},{"nctId":"NCT00710983","phase":"NA","title":"Investigating the Mortality and the Morbidity Impact of Oral Polio Vaccine at Birth","status":"UNKNOWN","sponsor":"Bandim Health Project","startDate":"2008-07","conditions":"Infant, Newborn, Healthy","enrollment":""},{"nctId":"NCT00348881","phase":"PHASE3","title":"Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":2133},{"nctId":"NCT01825109","phase":"PHASE3","title":"Improving Rotavirus Vaccine Immune Response","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2010-07","conditions":"Healthy Infants, Mothers","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":932,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oral Polio Vaccine (OPV)"],"phase":"phase_3","status":"active","brandName":"Biological: oral polio vaccine","genericName":"Biological: oral polio vaccine","companyName":"Biomed Industries, Inc.","companyId":"biomed-industries-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Oral polio vaccine stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by delivering live attenuated (weakened) virus that replicates in the gastrointestinal tract. Used for Poliomyelitis prevention in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}